Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Original Source
Read the full article at Cnbc →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.